Finance

Lists
Why is CSPCY down 7,53%?
Dive Deeper
CSPCY:OTCMKTS
CSPC Pharmaceuticals Group ADR
4,45 $
-7,53%
(-0,36) 1D
9 հոկ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CSPCY...
Open
4,45 $
High
4,45 $
Low
4,45 $
Mkt. cap
104,63 մլրդ
Avg. vol.
1,62 հզր
Volume
849,00
52-wk high
5,46 $
52-wk low
3,26 $
Beta
0,37
Shares outstanding
2,88 մլրդ
No. of employees
19 հզր
Open
4,45 $
High
4,45 $
Low
4,45 $
Mkt. cap
104,63 մլրդ
Avg. vol.
1,62 հզր
Volume
849,00
52-wk high
5,46 $
52-wk low
3,26 $
Beta
0,37
Shares outstanding
2,88 մլրդ
No. of employees
19 հզր
News stories
From web sources and news partners
Profile
CSPC Pharmaceutical Group researches, develops, manufactures and sells pharmaceutical products. Its headquarters is in China's Hebei Province. CSPC produces both active pharmaceutical ingredient and formulations. API products include penicillin, cefalosporins, synthetic vitamins, caffeine and ranitidine. Formulations include antibiotics, butylphthalide and analgesics, in addition to nearly 1,000 other products. CSPC's 15,000 employees are divided among more than ten subsidiaries, including CSPC Zhongrun, Weisheng, Zhongnuo and NBP. CSPC Pharma's total assets are valued above RMB 8 billion. In 2007, CSPC Pharma achieved sales of RMB 8 billion and net income of RMB 485 million. Direct exports of US$300 million ranked CSPC first among China's pharmaceutical enterprises. One subsidiary, China Pharmaceutical Group Co., Ltd is based in Hong Kong. It is listed on the Hang Seng China-Affiliated Corporations Index. In 2003 and 2004, China Pharma was listed as one of 100 excellent listed companies with turnover less than $1 billion. CSPC Pharma is recognized as one of China's "500 Most Valuable Chinese Brands" and "Top 500 Chinese Enterprises." Wikipedia
About CSPC Pharmaceuticals Group ADR
CEOZhang Cuilong
Employees18,6 հզր
Founded1992
Headquarters-
Sector-
Previous reportsAll values in HKD
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
6,62 մլրդ
6,11 մլրդ
6,47 մլրդ
12,13 մլրդ
Cost of goods sold
2,28 մլրդ
2,11 մլրդ
2,20 մլրդ
2,24 մլրդ
Cost of revenue
2,28 մլրդ
2,11 մլրդ
2,20 մլրդ
2,24 մլրդ
Research and development expenses
1,50 մլրդ
1,62 մլրդ
1,40 մլրդ
1,63 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,97 մլրդ
1,87 մլրդ
1,89 մլրդ
1,89 մլրդ
Operating expense
3,47 մլրդ
3,49 մլրդ
3,29 մլրդ
3,51 մլրդ
Total operating expenses
5,75 մլրդ
5,60 մլրդ
5,49 մլրդ
5,75 մլրդ
Operating income
869,63 մլն
514,71 մլն
973,82 մլն
6,38 մլրդ
Other non operating income
645,14 մլն
-470,42 մլն
181,80 մլն
11,92 մլն
EBT including unusual items
1,18 մլրդ
505,59 մլն
1,13 մլրդ
6,40 մլրդ
EBT excluding unusual items
1,37 մլրդ
186,56 մլն
1,13 մլրդ
6,35 մլրդ
Income tax expense
222,47 մլն
165,64 մլն
243,25 մլն
825,70 մլն
Effective tax rate
18,78%
32,76%
21,46%
12,91%
Other operating expenses
-
-
-
-
Net income
963,54 մլն
370,72 մլն
859,79 մլն
5,23 մլրդ
Net profit margin
14,56%
6,06%
13,30%
43,16%
Earnings per share
-
-
-
-
Interest and investment income
-
195,87 մլն
-
91,68 մլն
Interest expense
-104,94 մլն
-6,76 մլն
-11,01 մլն
-2,30 մլն
Net interest expenses
-104,94 մլն
189,12 մլն
-11,01 մլն
89,37 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
1,14 մլրդ
802,06 մլն
1,26 մլրդ
6,67 մլրդ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google Apps